U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Plasma processing device with anaphylatoxin remover

Patent 4963265 Issued on October 16, 1990. Estimated Expiration Date: Icon_subject May 6, 2008. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

Re31688

3742946

Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
Patent #: 3998946
Issued on: 12/21/1976
Inventor: Condie ,   et al.

Blood fractionation
Patent #: 4081431
Issued on: 03/28/1978
Inventor: Stephan, et al.

Plasmapheresis apparatus
Patent #: 4086924
Issued on: 05/02/1978
Inventor: Latham, Jr.

Method and apparatus for extravascular treatment of blood
Patent #: 4103685
Issued on: 08/01/1978
Inventor: Lupien ,   et al.

Ion exchanger treatment of citrate-stabilized plasma
Patent #: 4170590
Issued on: 10/09/1979
Inventor: Stephan ,   et al.

Artificial kidney
Patent #: 4212738
Issued on: 07/15/1980
Inventor: Henne

Variable volume plasma treatment chamber for an apparatus for the extracorporeal treatment of disease
Patent #: 4223672
Issued on: 09/23/1980
Inventor: Terman ,   et al.

Dialyzing membrane with adsorbent layer
Patent #: 4267047
Issued on: 05/12/1981
Inventor: Henne ,   et al.

More ...

Inventors

Assignee

Application

No. 191039 filed on 05/06/1988

US Classes:

210/638, Including ion exchange or other chemical reaction210/502.1, Sorptive component containing210/646, Hemodialysis210/651, Removing specified material210/691, From aqueous material210/908, Organic604/6.06Arterial and venous needles

Examiners

Primary: Jones, W. Gary

Attorney, Agent or Firm

International Classes

B01D 039/00
B01D 061/58
B01D 015/08

Abstract

Blood derived fluids are subjected to modification resulting in the production of anaphylatoxins. The anaphylatoxins may then be removed by passing the modified blood through silicic acid particles in an amount sufficient to substantially reduce the anaphylatoxins, while still retaining the other blood components and without affecting adversely the use of the blood for the patient.

PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
PatentsPlus: add to cart
PatentsPlus: add to cartIntelligent turbocharged patent PDFs with marked up images
$16.95more info
 
Sign InRegister
Username  
Password   
forgot password?